Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilar Pathway Quickly Becoming Crowded In U.S.

This article was originally published in The Pink Sheet Daily

Executive Summary

Interactive chart of growing 351(k) pipeline shows that while Phase III is dominated by big players, pure-play biosimilar companies are beginning to emerge.

Advertisement

Related Content

Biosimilars Education: Oncobiologics/Premier Deal Aims To Boost Adoption, Data Collection
Pfizer Will Retain Infliximab Biosimilar In US After Hospira Acquisition
As Biosimilar Meeting Requests Rise, So Do FDA's Performance Goal Challenges
FDA View On Amarin Disclosures Undercuts 'Same Labeling' For Biosimilars – AbbVie
Biosimilar User Fee Collections Climb; Application Growth Less Clear
Samsung’s Humira Biosimilar Set For Filings As It Completes Phase III
Amgen Seeks To Knock Out Humira Patents Through IPR Process
Biosimilar Sponsors Looking To Avoid ‘Patent Dance’ Turn To Inter Partes Review
Sandoz U.S. President Peter Goldschmidt: An Interview With “The Pink Sheet” DAILY

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS078572

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel